YaoSu Tech Secures 200 Million RMB to Embed 'AI + Organ-on-a-Chip' into Drug Discovery
business#ai for biology📝 Blog|Analyzed: Apr 9, 2026 02:47•
Published: Apr 9, 2026 02:36
•1 min read
•36氪Analysis
YaoSu Technology is taking a massive leap forward by securing 200 million RMB in Series A funding to revolutionize the pharmaceutical industry. By combining 多模态 AI with organ-on-a-chip technology, they are actively paving the way to replace traditional animal testing and drastically accelerate drug discovery. This incredible innovation highlights a bright future where AI-driven biological platforms become the gold standard for precision medicine and highly efficient research.
Key Takeaways
- •The FDA's new policies are highly encouraging the use of AI and organ-on-a-chip technologies over traditional animal testing for drug reviews.
- •YaoSu Tech has seen exponential revenue growth by partnering with major global pharma and cosmetics companies like Sanofi, Pfizer, and L'Oréal.
- •Clinical trials using AI image analysis and organ chips for gynecological cancers have shown a remarkable 100% prediction accuracy in early feedback.
- •The company is focusing on building an integrated closed-loop of organ chips, AI, and automation to reverse-drive new drug discovery.
Reference / Citation
View Original"At this stage, our focus is no longer on single-point model capabilities, but on building an integrated closed-loop of 'organ-on-a-chip + AI + automation', thereby creating a system that can continuously generate data, understand mechanisms, and reversely drive new drug discovery."